

**Supplemental Table S1. Tentatively identified metabolites that are significantly downregulated or upregulated in siAK2 treated cells.**

<b>Metabolite</b>	<b>m/z</b>	<b>Fold changes</b>	<b>P value</b>
Ganglioside GA2 (d18:1/12:0)	1087.6534	0.01	0.01539
Somatostatin fragment 3-14	773.3400	0.03	0.01807
Neuromedin B (4-10)	305.4492	0.19	0.02961
Hydrogen carbonate	105.9646	0.20	0.03952
3-Sulfopyruvic acid	212.9455	0.23	0.01008
Cysteamine	101.0629	0.42	0.00918
Ganglioside GM3 (d18:0/18:1(11Z))	632.4060	0.50	0.02412
SM(d18:0/14:0)	760.6126	61.20	0.04082
SM(d18:1/12:0)	730.5649	6.30	0.00526
PE(MonoMe(13,5)/MonoMe(11,5))	834.6261	4.80	0.02324

**Supplemental Table S2. Tentatively identified metabolites that are significantly downregulated or upregulated in siPGK1 treated cells**

<b>Metabolite</b>	<b>m/z</b>	<b>Fold changes</b>	<b>P value</b>
Somatostatin fragment 3-14	1087.6534	0.12	0.01539
3-(3,5-Diiodo-4-hydroxyphenyl) lactate	909.7448	13.00	0.01501
Cer(d18:1/24:1(15Z))	345.3312	2.80	0.01844
TG (20:0/24:0/o-18:0)	1065.8965	2.30	0.04961